PLAU and cancer: Another peptide-based inhibitor, the A6 peptide, a non-enzymatic fragment derived from uPA’s connecting domain, has shown anti-metastatic and anti-angiogenic activity across several cancer types by interfering with uPA-mediated cell signaling.